Extended Data Fig. 1: Patient demographics, clinical characteristics, and toxicity.
From: Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
(A, B) Demographics and clinical characteristics of all evaluable patients (n = 19) (A) and biomarker-evaluable patients (n = 16) stratified by autogene cevumeran responders and non-responders (B). (C) Frequency of grade 1 and 2 adverse events attributable to atezolizumab (left) and vaccine (right) in evaluable patients who received each drug. n = individual patients. Data are n (%) unless noted. P values by two-tailed Mann-Whitney test for numerical variables and Fisher’s exact test for categorical variables.
